Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.

about

Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.

Item

http://www.wikidata.org/entity/Q39457369

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Insights into the management o ...... ttings: a Mexican perspective.

@en

Insights into the management o ...... ttings: a Mexican perspective.

@nl

type

Item

label

Insights into the management o ...... ttings: a Mexican perspective.

@en

Insights into the management o ...... ttings: a Mexican perspective.

@nl

prefLabel

Insights into the management o ...... ttings: a Mexican perspective.

@en

Insights into the management o ...... ttings: a Mexican perspective.

@nl

P1476

Insights into the management o ...... ettings: a Mexican perspective

@en

P2093

Andrés Gomez-de-León

http://www.w3.org/2001/XMLSchema#string

Guillermo J Ruiz-Delgado

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Generic oncology drugs: are they all safe?

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

P304

809-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2017.1360180

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David Gómez-Almaguer

Guillermo J Ruiz-Argüelles

P577

2017-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28742419

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

chronic myeloid leukemia